CMS Targets Leadless Pacers For Medicare Coverage Analysis
This article was originally published in Clinica
Executive Summary
The Medicare agency signaled that it plans to establish a national coverage policy for leadless pacemakers in a memo issued May 18. The memo comes about one month after FDA approved the first such product, Medtronic’s Micra transcatheter leadless single-chamber pacemaker.
You may also be interested in...
Leadless Pacers Would Only Be Covered In Clinical Trials Under Medicare Proposal
The proposed national coverage policy, which was generated from an internal request by the US Medicare agency, would provide Medicare coverage of leadless pacemakers only if they are part of an FDA-approved trial that evaluates peri-procedural complications, post-procedural complications, long-term outcomes, and the influence of patient characteristics on outcomes.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.